ArticleFrontiers in endocrinology2026
Association between glycometabolic indicators and risk of early vascular aging and their predictive value.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early vascular aging (EVA) elevates cardiovascular risk, and glycometabolic dysfunction is closely associated with arterial stiffness. Seven markers including TyG, CHG and HOMA-series indices were compared to explore their independent correlations and discriminative value for prevalent EVA among physical examinees. Methods: This retrospective cross-sectional study enrolled 555 participants who underwent baPWV testing, identified from routine health-check records. Baseline data, biochemical indicators and seven glycometabolic indices were collected. Logistic regression, Spearman correlation and ROC analyses were performed to assess associations and diagnostic performance. Results: Totally 156 participants had prevalent EVA. All seven glycometabolic markers were independently associated with prevalent EVA after confounding adjustment. The CHG index showed strong correlation with mean baPWV (r=0.402, P<0.001). ROC analysis indicated modest discriminative performance for prevalent EVA across all markers; HbA1c yielded the highest observed AUC (0.690), while the TyG index achieved the highest observed discriminative sensitivity (70.51%). Conclusions: In this retrospective cross-sectional study, all seven glycometabolic indicators were independently associated with prevalent EVA and showed modest discriminative capacity for prevalent EVA within the study sample. The TyG index exhibited the highest observed discriminative sensitivity, while HbA1c showed the highest observed AUC. These two indices may be considered potential low-cost auxiliary markers for identifying prevalent EVA in health-check settings; bootstrap internal validation and prospective external validation are required before broad clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.